Abbott Laboratories

ABT
WATCH
56.9
/ 100
contested conviction

AI Committee Synthesis

6 analysts weighed in with 50% agreement on a bullish lean. Risk Analyst: Low leverage (debt-to-equity 0.25) -- balance sheet can absorb a shock. Growth Analyst: EPS declining -53.6% YoY despite any revenue growth. Overall recommendation: WATCH.

Want the full analysis?

Trade plan, entry/stop/target levels, individual analyst breakdowns, and real-time AI Q&A for ABT — free to start.

Get Full Access →